Company: BIAF
Filing Date: 2025-05-05
Form Type: S-1/A
Source: 0001641172-25-008629
Chunk: 187

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-05
Form: S-1/A
Chunk 187
---
 option to execute a securities purchase agreement with us. In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the investors which enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with a means to enforce the following covenants uniquely available to them under the securities purchase agreement, including: (i) timely delivery of shares; (ii) a covenant to not enter into variable rate transactions for a period of 12 months following the closing of the offering, subject to certain exceptions, including that the prohibition against entering into an “at the market” offering will expire 45 days following the closing of the offering; (iii) a covenant to not enter into any financings for 60 days from closing of the offering; and (iv) indemnification for breach of contract. The nature of the representations, warranties and covenants in the securities purchase agreements shall include:

| ● | standard                                                                                                                            
 issuer representations and warranties on matters such as organization, qualification, authorization, no conflict, no governmental   
 filings required, current in SEC filings, no litigation, labor or other compliance issues, environmental, intellectual property and 
 title matters and compliance with various laws such as the Foreign Corrupt Practices Act; and                                       |

| ● | covenants                                                                                                                               
 regarding matters such as registration of warrant shares, no integration with other offerings, no stockholder rights plans, no material 
 nonpublic information, use of proceeds, indemnification of purchasers, reservation and listing of shares of Common Stock, and no        
 subsequent equity sales for 45 days, subject to certain exceptions.                                                                     |

This offering will terminate on May 15, 2025, unless we decide to terminate the offering (which we may do at any time in our discretion) prior to that date. We will have one closing for all the securities purchased in this offering. The combined public offering price per share (or Pre-Funded Warrant) and May 2025 Warrants will be fixed for the duration of this offering.

We expect to deliver the shares and other securities to the purchasers in the offering on or about [___], 2025, subject to satisfaction of certain conditions. There is no minimum number of securities or amount of proceeds that is a condition to closing of this offering.

Fees and Expenses

The following table shows the per share and accompanying May 2025 Warrants and per Pre-Funded Warrant and accompanying